Pralay Mukhopadhyay

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

Paul Baverel, Vincent F. S. Dubois, Chao Yu Jin et al. · Clinical Pharmacology & Therapeutics · 2017 · 151 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations

Mario Ouwens, Pralay Mukhopadhyay, Yiduo Zhang et al. · PharmacoEconomics · 2019 · 91 citations · Full text

Public Health, Biostatistics, Oncology +17

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer

Scott McMeekin, Don S. Dizon, James Barter et al. · Gynecologic Oncology · 2015 · 76 citations

Medicine, Oncology, Pharmacology +9

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Gabriel N. Hortobágyi, Henry Gómez, Rubi K. Li et al. · Breast Cancer Research and Treatment · 2010 · 66 citations · Full text

Medicine, Oncology, Pharmacology +11

Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients

Sriram Sridhar, Luis Paz‐Ares, Hao Liu et al. · Clinical Lung Cancer · 2019 · 60 citations · Full text

Medicine, Oncology, Medical Oncology +16